Research Priorities - Cancer
  • Article
  • May 13 2022

Nearly three decades after first discovering the tumor-suppressing Par-4 “super gene” that has been shown to kill cancer cells, a team of researchers at the University of Kentucky Markey Cancer Center is now learning about its role in preventing obesity.

  • Blog
  • May 10 2022

This blog is written by B. Mark Evers, M.D., director of the University of Kentucky Markey Cancer Center, in recognition of National Cancer Research Month.

  • Article
  • Apr 14 2022

The UK Markey Cancer Center joins Caris' extensive network of leading cancer institutions committed to utilizing clinical data to advance patient care and outcomes.

  • Article
  • Mar 31 2022

There is evidence that liquid biopsies obtained from a blood sample have the potential to replace tumor biopsies requiring patients to undergo a surgical procedure.

  • Article
  • Mar 29 2022

The University of Kentucky Markey Cancer Center Foundation received a $1 million gift to create the world’s first distinguished professorship in neuroendocrine tumor (NET) research.

  • Article
  • Mar 16 2022

Junior Lauren Hudson’s passion for research started her freshman year, when Nathan Vanderford, the assistant director for research in the UK Markey Cancer Center, reached out to her about participating in his research program.

  • Podcast
  • Feb 21 2022

In this episode of Behind the Blue, Evers takes us through some of the most important milestones and accomplishments of the Markey team during his time at UK, and discusses plans for Markey’s future.

  • Article
  • Feb 21 2022

University of Kentucky and UK HealthCare experts will be featured in a three-part series by Kentucky Educational TV (KET) that examines the causes, impact and new developments in the treatment of lung disease in Kentucky.

  • Article
  • Feb 18 2022

UK HealthCare announced a historic $10 million gift from Central Bank to support expanded patient care at Markey Cancer Center, the largest in UK HealthCare history.

  • Article
  • Feb 9 2022

The laboratory of Christine Brainson is defining new potential therapy options for two molecular subtypes of lung cancer.